ANXA5 and neoplasm: Similar to that observed in TC-1 tumor model, AnxA5-AH5 administration following cisplatin resulted in the best tumor control, prolonged survival of mice, as well as the generation of the strongest systemic and tumor infiltrating AH5-specific CD8+ T cell response as compared to those that received other treatment regimens (Fig. 6b–e).